# Intratumoral Microdosing of Motolimod in HNSCC

> **NCT04272333** · EARLY_PHASE1 · TERMINATED · sponsor: **Presage Biosciences** · enrollment: 1 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Motolimod
- **BIOLOGICAL:** Nivolumab
- **COMBINATION_PRODUCT:** Motolimod + Nivolumab

## Key facts

- **NCT ID:** NCT04272333
- **Lead sponsor:** Presage Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-15
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Partner Termination
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272333, "Intratumoral Microdosing of Motolimod in HNSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04272333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*